A B S T R A C T lopanoic acid has been shown to block thyroxine (T4)-5'-monodeiodination in rat anterior pituitary in vitro. To test the hypothesis that the acute decrease in thyrotropin (TSH) after infusion of T4 into hypothyroid rats requires intrapituitary T4 to 3,5,3'-triiodothyronine (T3) conversion, the effect of iopanoic acid treatment on the generation of nuclear T3 from intrapituitary conversion and the response to TSH were compared in control and iopanoic acid-treated animals. 5 mg/100 g body weight iopanoic acid given 24, 16, and 1.5 h before administration of 1251-T4 reduced the quantity of pituitary nuclear 125I-T3 from local (intrapituitary) T4 to T3 conversion by 60-100%. In association with inhibition of intrapituitary T4 to T3 conversion, there was an increase in the binding of 1251-T4 to the nuclear receptor of the pituitary but the total iodothyronine content of the nuclei was still less than half of the nuclear iodothyronine in control animals. lopanoic acid did not affect the nuclear/plasma ratio of injected 131I-T3 in the same animals, but did appear to impair 131I-T3 clearance or reduce its distribution volume. Treatment with iopanoic acid did not reduce the quantity of nuclear 1251-T3 in the liver, kidney, or heart of the same animals more than expected from the changes in serum 1251-T3. In control hypothyroid animals, 800 ng/100 g body weight T4 caused a reduction in TSH to 41% of its initial value 3 h after injection. In animals pretreated with iopanoic acid, the mean TSH was not significantly decreased from the initial value by T4 injection. Iopanoic acid pretreatment did not interfere with the acute TSH response of chronically hypothyroid rats to 70 ng of T3/100 g body weight. These Received for publication 11 February 1978 and in revised form 12 March 1979. results establish that intrapituitary generation of T3 from T4 is required for the acute decrease in TSH which occurs after T4 infusion. The data also are consistent with the concept that it is the nuclear binding of the T3 generated from T4 which initiates the inhibition of TSH release.
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INTRODUCTION
We have previously demonstrated a chronological and quantitative relationship between the acute inhibition of thyrotropin (TSH)l release by injected 3,5,3'-triiodothyronine (T3) in chronically hypothyroid rats and the nuclear T3 specifically bound in the anterior pituitary (1, 2) . Although about 10-fold larger amounts are required, thyroxine (T4) also acutely inhibits thyrotropin (TSH) release. The degree to which TSH release is inhibited after T4 also parallels the nuclear T3 content (1, 2) . In these acute experiments, the bulk (>70%) of the nuclear T3 after T4 injection is derived from intrapituitary T4-5'-monodeiodination. We have also reported that neither the TSH inhibition nor the increase in nuclear T3 after T4 injection were blocked by pretreatment of rats with 6-n-propyl-2-thiouracil (PTU) (2) despite the fact that this has been shown to block -70% of peripheral T4-5'-monodeiodination in rats (3, 4) . Because pituitary T4-5'-monodeiodination was not inhibited by PTU, the hypothesis that T4 to T3 conversion was required for the effect of this dose of T4 on pituitary TSH release could not be tested using this agent. ' Abbreviations used in this paper: PTU, 6-n-propyl-2-thiouracil; T3, 3,5.3'-triiodothyronine; T4, thyroxine; TSH, thyrotropin.
Several years ago, Burgi et al. (5) reported that normal patients receiving iopanoic acid (Telepaque; Winthrop Laboratories, New York) for oral cholecystography had decreases in serum T3 associated with increases in serum T4 and TSH. Similar changes in serum T4 and T3 were recently reported for another oral cholecystographic agent, ipodate (Oragrafin; E. R. Squibb & Sons, Princeton, N. J.) by Wu et al. (6) in euthyroid and hyperthyroid subjects. Kaplan and Utiger (7) have also demonstrated that iopanoic acid blocks 5'-monodeiodination of both T4 and 3,3'5'-triiodothyronine (reverse T3) in rat liver homogenates (7) and similar effects have recently been observed in renal tissue homogenates as well.2 These reports led us to compare the effects of iopanoic acid and PTU on T4-5'-monodeiodination by rat anterior pituitary tissue with an in vitro system which we have recently d&scribed (8) . In confirmation of our in vivo results, incubation of anterior pituitary tissue with PTU did not inhibit T4 to T3 conversion (9) . However, in both tissue fragments and anterior pituitary homogenates, iopanoic acid blocked T4-5'-monodeiodination (9, 10) . The capacity of this agent to block both peripheral and intrapituitary T4 to T3 conversion suggested that it might be an appropriate tool to substantiate our hypothesis that intrapituitary T4 to T3 conversion is required for the acute response of TSH to T4 in the hypothyroid rat.
METHODS
Materials. T3 and T4 (free acid) were obtained from Sigma Chemical Co., St. Louis, Mo. lopanoic acid (Telepaque) was a gift of Dr. F. C. Nachod, Winthrop Laboratories, Sterling Drug Co., New York. 131I-T3 and 125I-T4 were labeled in the laboratory by previously described methods (11) . Rats were obtained from Zivic-Miller Laboratories, Allison Park, Pa., and were thyroidectomized by the supplier before shipment. They were held for 2-3 mo until growth plateaued before use in these experiments. Materials for immunoassay of rat TSH were kindly provided by the Pituitary Hormone Distribution Program of the National Institute of Arthritis, Metabolism, and Digestive Diseases.
Iopanoic acid injections. For a typical experiment, 125 mg of iopanoic acid was dissolved in 2.1 ml of 0.1 N NaOH. 2.5 ml of propylene glycol and 0.4 ml of 0.25 N NC] were added subsequently. The final solution was 25 mg/ml with respect to iopanoic acid in _0.03 N NaOH. Experimental rats were given 5 mg/100 g body weight i.p. 24, 16, and 1.5 h before injection of the labeled or unlabeled iodothyronines. Control animals were given injections of vehicle alone.
Injection of iodothyronines. Before injection of iodothyronines, serum was obtained for TSH, T3, and T4 measurements in all animals to confirm the hypothyroid state. In some experiments, TSH measurements were also obtained before iopanoic acid injections. Labeled or unlabeled iodothyronines were given in -0.5 ml of 10% hypothyroid rat serum in phosphate-buffered saline (pH 7.4) by jugular injection. In two experiments (A and B), 800 ng 1251-T4/100 g body weight was given 3 h and tracer 131I-T3 90 min before killing the rats. In a third experiment (C), the 1251-T4 and 131 I-T3were given simultaneously 3 h before quantitation of serum and nuclear iodothyronines. Because of the requirement for large quantities of 125I-T4 (rats received about 100 ,uCi 125I-T41100 g body weight), the numbers of rats were limited to six or eight for each experiment.
Calculation of nuclear and plasma 125I-T3, 131I-T3, and '251-T4. These determinations were made by methods previously described in detail with one major modification (1, 2, 12, 13) . Previously, we have used TCA precipitation of serum to estimate the quantity of serum 131I-T3. Our recent unpublished studies have indicated that this approach is not optimal. Affinity chromatographic isolation of T3 with specific T3 antibody-Sepharose conjugates has shown that only 50-70% of the TCA-precipitable 1311 1.5 h after 1311 injection was actually 31I-T3. This method has been previously described (13) . With longer intervals subsequent to injection, the fraction of TCA-precipitable 1311 that was T3 was even lower. These results have been confirmed by chromatography of butanol extracts of serum. The TCA-precipitable, but non-T3, material is presumably T4 as well as the other unidentifiable degradation products of 31I-T3, such as 3,3'-diiodothyronine. The difference between TCA-precipitable serum 1311 and 131I-T3 becomes appreciable 1-1.5 h after injection of the T3 isotope. Therefore, the following approach was developed. To establish that the recovery of T3 in the experimental rat serum samples was identical to that obtained in the pooled rat serum, I311-T3 (-100,000 cpm) was added to 0.1-ml aliquots of each rat's sera. These sera already contained 1,000-3,000 cpm 31I-T3 from the experimental injection. 131I-T3 recovery through the affinity and paper chromatographic procedure was determined and found to be identical to that for the same 131I-T3 added to pooled serum from normal rats. Accordingly, the following method was used to determine serum 31I-T3 and 125I-T3 concentrations. 0.1 ml of each rat serum (in duplicate) was incubated overnight with 0.25-0.5 ml anti-T3-Sepharose conjugate at 4°C as we have previously described (13) . Fresh 31I-T3 was added to pooled serum from other rats and subjected to the identical procedure at the same time. The Sepharose conjugate was washed, iodothyronines were extracted with methanol-2-N-NH4OH (99:1, vol/ vol, and were chromnatographed with added T3, T4, and iodide in tertiary amyl alcohol:hexane:2 N NH40H, 5:1:6 (2, 13). The T3 spot was located by chemical staining, and counted with appropriate corrections for paper backgrounid anid crossover of 1311 into the 125I spectrophotometer channiel. The recovery of 31I-T3 added to normal rat serumii varied from 17 to 35% using different Sepharose conjugates. This recovery factor was then applied to both the 13II-T3 and '25I-T3 in the experimental rat serum samples. This procedure was not modified from the earlier descriptioni (2). 31I-T3 accounited for 66-92% of the serum TCA-precipitable radioactivity in experiments A and B (1.5 h after 31I-T3 injection) and 28-61% of the TCA precipitable radioactivity in experiment C (3 h after '31I-T3 injection).
Miscellaneous. 1251-T3 conitaminationi of '25I-T4 was ineastired as previously described (2, 13). 125I-T3 was 0.9, 1.1, and 1.1% of the 125I-T4 isotopes used in experiments A, B, and C, respectively. '31I-T4 in '31I-T3 varied from 0.5 to 1%, but the use of the affinity method for estimation of serumil 1311_ T3 obviated the need for correction of the TCA-precipitable 31I-T3 for the 10-fold relative increase in 131I-T4 conlcentration which occurs during the initial distribution phases of the two isotopes after injection (12) . Assays for serumiii TSH were performed as previously described (14) . The effects of pretreatment of rats with iopanoic acid on T3 and T4 metabolism were studiedl vith two protocols. In experimeints A and B, 1251-T4 was given 3 h before, and 131I-T3 1.5 h before analysis of serum and nuclear radioactivity. This time interval for T3 injection was selected because 90 min appears to be the approximate time of maximal nuclear occupancy by T3 in hypothyroid rat anterior pituitary nuclei (1) . Because we wished to determine the contribution of serum 125I-T3 to nuclear 1251-T3 3 h after 125I-T4 injection, it was necessary that the pituitary nuclear/serumii T3 ratio be measured at a time when the specific activity of T3 in the nuclear and the plasma-cytoplasm compartment were identical. This situation is only present at the time after injection that nuclear tracer T3 is maximal (12, (15) (16) (17) . In experimenit C, both 131I-T3 and '25I-T4 were given simultaneously 3 h before killing the rats. Because 125I-T3 contamiiniation of the 1251-T4was known, this protocol allowed determination of the fate of the 1251-T3 contaminant. Amounlts of serum or nuclear '251-T3 in excess of that due to contaminant in these animals could then be attributed to in vivo T4-5'-monodeiodination.
RESULTS OF EXPERIMENTS A AND B
Radioactivity in plasma. The data presented in Table I indicate that pretreatment of rats with 5 mg/ 100 g body weight iopanoic acid 24, 16, and 1.5 h previously had no statistically significant effect on the acute metabolism of 131I-T3 and '251-T4. However, in both experiments, serum '31I-T3 was higher in rats receiving iopanoic acid than in controls. In the last column of Table I is shown the concentration of serum '251-T3 3 h after injection. As is indicated in the table, serum '251-T3 is either that injected as a contaminant or derived from in vivo 5'-monodeiodination of 1251-T4 in the liver and kidney, and then appearing in plasma. In both experiments, 1251-T3 was higher in the vehicleinjected groups, but again the difference was too small to be statistically significant. The effects of iopanoic acid pretreatment on these parameters is discussed again under experiment C.
Nuclear 131I-T3anid 1251-T3. Results ofthe analyses of nuclear iodothyronine in anterior pituitary, liver, kidney, and heart from experiments A and B are shown in Table II . Nuclear 131I-T3 was slightly higher in the anterior pituitary and liver of iopanoic acid-treated rats in experiment A and in the anterior pituitary of experiment B, but the serum 131I-T3 Mean±SE.
* Animals were given iopanoic acid, 5 mg/100 g body weight i.p., 24, 16, and 1.5 h before 1251-T4 injection. Controls received equivalent vehicle. 131I-T3 was given 1.5 h after 125I-T4 and rats were killed 1.5 h later. There were three animals in each group (vehicle and iopanoic acid) in each experiment.
I Results are not corrected for the contribution of serum 1251-T3 to nuclear '25I-T3. § P < 0.005 for difference from vehicle. There were no other effects of iopanoic acid pretreatment which were statistically significant.
was also higher in these animals (Table I) . Therefore, the nuclear/serum ratio for '31I-T3 (middle portion of Table II) was not significantly different for either experiment in any of the four tissues examined. These results indicate there is no substantial effect of iopanoic acid on the distribution of T3 between cell nuclei and serum in these organs. The data for nuclear 1251-T3are shown in the right hand portion of Table II. These figures include both '251-T3 from plasma and that generated in the tissue. In both experiments, anterior pituitary nuclear 125I-T3 was significantly lower in the iopanoic acid-treated animals (P < 0.005). Nuclear 125I-T3 was slightly less in the liver, heart, and kidney of iopanoic acid-treated rats than in controls. However, the small differences were not sufficient to be statistically different. It should also be noted that in experiment B particularly, serum 125I-T3 was somewhat lower in the iopanoic acid-treated animals ( Table I) .
As there was no significant difference in nuclear 1251-T3 in the iopanoic acid-treated rats in any other tissues, analysis of the specific sources of nuclear 1251_ T3 is presented only for the anterior pituitary (Table  III) . As was apparent from Table II , there was no significant difference in nuclear 131I-T3 as a result of iopanoic acid treatment in either experiment A or B, while the 1251-T3 was reduced in the treated animals. Because plasma 1251-T3 contributes to nuclear 1251-T3, it is necessary to estimate and deduct this contribution to evaluate the effect of iopanoic acid on intrapituitary T4 to T3 conversion. The contribution of plasma 1251_ T3 to nuclear 1251-T3 was determined by multiplication of the serum 1251-T3 by the nuclear/serum ratio for 13 I-T3 as we have previously described (1, 2, 12) . In experiment A, serum 1251-T3 accounted for over onehalf of the nuclear 1251-T3 in both groups of animals. In experiment B, serum 125I-T3 accounted for about 40% ofnuclear 125I-T3 in the control animals, and for virtually all of the nuclear 1251-T3 in the iopanoic acid-treated group. The estimated nuclear 125I-T3 derived from intrapituitary 5'-monodeiodination was reduced by 60% in experiment A and by 90% in experiment B (P < 0.01).
Because the specific activity of 1251-T3 derived from distal ring-labeled 1251-T4 is only one-half that of the precursor, calculation ofthe T3 generated requires multiplication of the net 1251-T3 by a factor of 2. The results of this calculation are presented in the last column of Table  IV . lopanoic acid (or vehicle) was given 24, 16, and 1.5 h before injection of 31I-T3 and 1251-T4 to groups of four hypothyroid rats. The percentage dose of l311_ T3 in the sera of iopanoic acid-treated rats, 0.32+0.02
(mean±SE) was about twice that in control animals (P < 0.01). The serum 1251-T4 concentration was also statistically significantly higher in these iopanoic acidtreated animals but the serum 125I-T3 was again not significantly lower in the treated group. This is true despite the fact that the 125I-T3 concentration in controls is roughly twice that of the iopanoic acid-treated group. Because the two isotopes were given simultaneously, and because the 1251-T3 contamination was known, it was possible to calculate the amount of 1251-T3 contaminant still present in each animal by use of the '31I-T3 distribution. The contribution of contaminant 1251-T3 to serum 1251-T3 is given in the last column of Table IV . In control animals it was 1.6 x 10-3% of the dose/ml. In the iopanoic acid-treated group, the contaminant accounted for all of the serum 1251-T3; that is, there was no new plasma 1251-T3 in these rats. In the vehicle-treated animals, the difference between the 125I-T3 contaminant and the total 1251-T3 must arise from peripheral T4 to T3 conversion. This newly formed 125I-T3 constitutes about 75% of the 1251-T3 present 3 h after injection. The analysis of nuclear T3 and nuclear/serum T3 ratios in these rats is presented in the lower portion of range of the results. Nuclear 131I-T3 in liver, heart, and kidney were all statistically significantly higher in iopanoic acid-treated animals, although the nuclear/ serum ratios were not different. Therefore, these differences in nuclear '35I-T3 can be attributed to the higher concentrations of 31I-T3 present in the sera of the iopanoic acid-treated rats. The pattern of results for nuclear 1251-T3 and the nuclear/serum 1251-T3 ratios is quite similar to that obtained in experiments A and B. In anterior pituitary, the nuclear T3 was only 25+8 x 10-4% of the dose/mg DNA in iopanoic acidtreated rats while controls had 112+17 x 10-4% of the dose/mg DNA (P < 0.005). Neither the nuclear 125I-T3 nor the nuclear/serum 125I-T3 ratio were different in any of the other tissues studied. The results in table IV indicate that there was an apparent effect of iopanoic acid on either the volume of T3 distribution or the metabolic clearance of T3 in these animals and this is discussed further below. The results of the analyses of the sources of pituitary nuclear T3 in experiment C is shown in Table V . Because 131I-T3 was given 3 h before killing the rats, the nuclear/serum 31I-T3 ratio obtained is not appropriate for estimating the contribution of serum 125I-T3 to nuclear 125I-T3 in the pituitary. The pituitary nuclear/serum T3 ratio increases with time after the time of maximal nuclear occupancy as we have shown previously in euthyroid rats (12) . In addition, some 12-18 h is required for serum 1251-T3 to reach a peak after injection of 125I-T4 to euthyroid rats (12) . A similar, or perhaps even longer, period would presumably be required in the hypothyroid animal. Therefore, the newly formed 1251-T3 is rising steadily and that amount generated in the hour or so previous to killing the rat has not achieved complete equilibration with the pituitary nuclear T3 receptors. For this analysis, we have used the nuclear/serum 131I-T3 ratio obtained in experiments A and B, recognizing that this is probably an overestimate of the appropriate nuclear/serum T3 ratio to be applied to the serum 125I-T3 in these animals.
In the first two columns of 802±187 § 31±7" * Includes both locally derived and plasma '25I-T3. 4 Portion of sample lost; not included in mean. § P < 0.025. 1" P < 0.005. ¶ P < 0.001 for difference from vehicle-injected rats by unpaired t test.
was statistically significapt only for the rats in Experiment B. Nevertheless, there was a decrease in the fraction of nuclear iodothyronine that was T3 from a mean of 76% in the three control groups to a mean of 37% in the iopanoic acid-treated groups. This difference was highly significant in each experiment. However, because the increment in nuclear 1251-T4 was substantially less than the decrement of nuclear T3, especially considering the fact that the specific activity of the 125I-T3 is only one-half that of 1251-T4, the total nuclear iodothyronines were still reduced in iopanoic acid-treated animals compared with controls.
Effect ofiopanoic acid administration on TSH response to injected iodothyronines Results of injection of 800 ng T,/100 g body weight to chronically hypothyroid rats with and without iopanoic acid pretreatment are shown in Fig. 1 FIGURE 1 Acute response of chronically hypothyroid rats to 800 ng T4100 g body weight i.v. One group received vehicle alone (alkaline 50% solution of propylene glycol). The other group received three injections of iopanoic acid, 5 mg/100 g body weight i.p., 24, 16, and 1.5 h before injection of T4. value 3 h after T4 injection (P < 0.005). The magnitude of this suppression is similar to our previous results with this T4 dose (1, 2, 18 ). In animals treated previously with three injections of iopanoic acid, the mean serum TSH 3 h after identical quantities of T4 was not significantly altered. Thus, iopanoic acid pretreatment prevented the response of the pituitary to the dose of injected T4.
Because the apparent blockade of TSH response might have been due to nonspecific effects of iopanoic acid, the response of chronically hypothyroid rats to 70 ng/100 g T3 was also evaluated. Results of these studies are shown in Fig. 2 . In vehicle-injected rats, TSH was suppressed by 40% (P < 0.05) in agreement with results of earlier studies (1, 18) . The response to T, was not blocked by iopanoic acid pretreatment, because in the animals so treated T3 caused suppression of TSH to 41% of the initial TSH level (P < 0.01) In other experiments not shown, the three iopanoic acid injections did not alter the basal TSH concentrations in these chronically hypothyroid rats.
DISCUSSION
The primary goal of these studies was to test the hypothesis that intrapituitary T4 to T3 conversion was required in order for T4 to inhibit acutely the release of TSH in chronically hypothyroid rats (1) . The blockade of the hepatic effect of T4 (but not T3) by PTU treatment has been shown by numerous investigators (19) (20) (21) (22) . Using tracer injections, Oppenheimer et al. demonstrated that this effect was due to impaired T4 to T3 conversion (3). The results of our own studies using radioimmunoassay of T3 in T4-treated animals confirmed these earlier studies (4, 18) . The fact that we did not find inhibition of intrapituitary T4 to T3 in vivo conversion by pretreatment of animals with PTU was most puzzling (2) . Although the same lack of effect has been recently demonstrated in vitro, the explanation is still unknown (9) . Whatever the cause, the lack of effect of this agent obviated a test of the importance of intrapituitary T4 to T3 conversion in T4-induced TSH suppression.
These results support our earlier speculation that intrapituitary T4 to T3 conversion is required for acute TSH suppression because pretreatment of rats with iopanoic acid prevented the response of the thyrotroph to injection of T4 but not to T3. Because the results of 131I-T3 injections demonstrated that there was no significant inhibition of 31I-T3 binding to the nuclei by iopanoic acid, the appropriate response of the hypothyroid rats to T3 in-jection was not unexpected. The fact that the response to T4 is blocked by pretreatment of animals with iopanoic acid in association with simultaneous inhibition of T4 to T3 conversion confirms the requirement for T4-5'-monodeiodination in the production of this acute effect by T4. Because the expected increase in nuclear T3 after T4 is blunted or inhibited in iopanoic acid-treated rats, the results are also consistent with the hypothesis that binding of T3 to the nuclear receptor initiates the sequence of events leading to the inhibition of TSH secretion. However, other actions not mediated through the nucleus but also requiring T3 could still be responsible for this effect.
Because the data from experiment C indicate that iopanoic acid inhibits T4 to T3 conversion in all tissues, documentation that it is the inhibition of intrapituitary T4 to T3 conversion which is responsible for Intrapituitary Thyroxine 5'-Monodeiodination and Biological Activitythe marked decrease in pituitary nuclear T3 is required. In our previous studies, we have provided data indicating that most of the nuclear T3 3 h after T4 administration to hypothyroid rats is the result of intrapituitary T4-5'-monodeiodination. Although we analyzed the sources of serum and pituitary nuclear 1251_ T3 as was done in experiment C (Table V) , this aspect of the earlier studies was not emphasized (1, 2) . For example, 3 h after injection of 1251-T4, we found =60% of the plasma '251-T3 was derived from newly generated 1251-T3 in these experiments (2) . This in turn accounted for about 20% of the noncontaminant pituitary nuclear '251-T3 (Appendix of [2] ). Therefore, 80% of the pituitary nuclear T3 was locally generated 3 h after T4 injection in this study. This is in close agreement with the estimate of 74% in Table V when data from animal one are excluded from the mean. At this time interval after T4 injection, the major portion of pituitary nuclear 1251-T3 is derived from pituitary T4-5'-conversion. The absence of nuclear 1251-T3 as in experiment C, or the marked decreases seen in experiments A and B, all indicate pituitary T4-5'-conversion must be markedly reduced. This is in good agreement with the potent effect of iopanoic acid in vitro (8, 9) . To summarize, the data suggest that at least 70-80% of pituitary nuclear T3 at 3 h is derived from intrapituitary T4 to T3 conversion. Although inhibition of peripheral hepatic and renal T4 to T3 conversion also occurs as a result of iopanoic acid treatment, this source contributes in only a minor way to pituitary nuclear T3 under these experimental circumstances.
Because T4 to T3 conversion is well recognized to occur in the liver and kidney, and iopanoic acid inhibits this process in vitro, the question may also be raised as to why no effects on nuclear 1251-T3 were apparent in these tissues. As we have previously demonstrated in both hypothyroid and euthyroid rats, intracellular T4 to T3 conversion in liver and kidney contributes only a small portion of the nuclear T3 in these tissues (2, 12) . For example, in euthyroid rats we calculated that roughly equal quantities of pituitary nuclear T3 were derived from plasma T3 and from intracellular T4 to T3 conversion (12) . In liver and kidney, only 28 and 14% of the nuclear T3 was estimated to derive from local intracellular T4 to T3 conversion, respectively. The reasons for these differences are not precisely known. Certainly one important influence is the fact that roughly 50% of T3 in the pituitary is in the nucleus, while only 5-10% of intracellular T3 is present on the nuclear receptor in liver and kidney cells (23) . This means that a fivefold greater fraction of any T3 generated will be bound to the nuclei of pituitary tissue as opposed to liver. Because intracellular T4 to T3 conversion is not a major source of nuclear T3 in these tissues, inhibition of '251-T4-5'-monodeiodination would not be expected to have an effect greater than that anticipated from the change in the plasma 1251-T3 concentration especially at relatively short time intervals after 1251-T4 injection. A further reason for the absence of a detectable effect in liver nuclei is that hepatic T4 to T3 conversion is reduced in hypothyroid rats, whereas pituitary T4 to T3 conversion is stimulated (8, 9, (24) (25) (26) .
In these studies, we provide new data with respect to the sources of nuclear T3 in cardiac tissue, which has not been studied previously. Apparently the nuclear receptors of the mycardial cells, like liver and kidney, are also predominantly dependent upon serum for nuclear T3, because there appears to be no specific inhibitory effect of iopanoic acid on nuclear 1251-T3 in this tissue. All ofthe modestly lower results for nuclear 1251-T3 in iopanoic acid-treated rats in tissues other than anterior pituitary can be explained in terms of the somewhat lower concentrations of serum '251-T3 in these animals. Although in none ofthe experiments was this difference in serum 1251-T3 statistically significant, the data in experiment C clarify a major reason for this phenomenon. At the same time that iopanoic acid inhibits T4-5'-monodeiodination, it also appears to inhibit the metabolic clearance ofT3, perhaps through a similar inhibition of deiodination. This is reflected in the fact that in all three experiments, the serum 1311-T3 was lower in vehicle than in iopanoic acid-treated rats. Although this might be interpreted as being a result of an iopanoic acid-induced reduction in the volume of T3 distribution, the fact that the difference between iopanoic acid-and vehicle-treated rats is greater at 3 h than at 1.5 h after injection suggests that it may be clearance that is affected. This process tends to reduce the differences in serum 1251-T3 in the two groups of animals. The iopanoic acid-treated rats have relatively complete impairment of T4 to T3 conversion, but serum 1251-T3 is present either due to impaired clearance of the contaminant or its distribution into a smaller volume than in controls. The vehicle-treated rats clear the contaminant more rapidly but generate new 125I-T3 in peripheral tissues. It should also be kept in mind that the percentage of the T3 dose per milliliter is a function of weight, and therefore some of the variation in plasma 131I-T3 values in the groups in Table I can be explained in part by weight differences.
For example, animal one in experiment A weighs almost 100 g more than animal two, and the serum 131I-T3 and 1251-T3 concentrations are the lowest of the three in that group. Similarly, animal three in experiment B is the smallest of the entire group, and this would certainly contribute to the fact that the serum 31I-T3 and 1251-T3 is substantially higher in that animal than in the other two.
The fact that nuclear T4 may increase when intrapituitary T4 to T3 conversion is decreased (Table   VI) In summary, these studies confirm our previous speculations regarding the requirement for conversion of T4 to T3 in the pituitary to obtain acute suppression of TSH release in chronically hypothyroid rats. The fact that the physiological effect of T4 is prevented at the same time the increase in nuclear T3 after T4 is also inhibited supports the concept that this effect of T4 is initiated by binding of locally produced T3 to the pituitary nuclear receptor. The results raise the distinct possibility that the impressive changes in serum T4 and TSH reported by Burgi et al. (5) in euthyroid subjects given iopanoic acid are not only due to an inhibition of hepatic and renal T4 to T3 conversion, but also to inhibition of intrapituitary T45'-monodeiodination.
